Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[IgD/kappa myeloma].

A K Golenkov, G P German, A R Zlatkina

    Terapevticheskii Arkhiv
    |January 1, 1984
    PubMed
    Summary

    This study details a rare IgD/kappa myeloma case, a specific immunochemical disease pattern. Findings suggest IgD/kappa myeloma follows a more favorable clinical course compared to IgD/lambda myeloma.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    [Inhibition of NF-kB Activation Decreases Resistance in Acute Myeloid Leukemia Cells to TRAIL-induced Apoptosis in Multicellular Aggregates].

    Biofizika·2016
    Same author

    [Disintoxication effect of levomycin and synthomycin].

    Antibiotiki·2014
    Same author

    [Gene expression of vascular endothelial growth factors and their receptors in different variants of the course of multiple myeloma].

    Terapevticheskii arkhiv·2013
    Same author

    [Effectiveness of bortezomib and bortezomib-containing programs for the treatment of recurrent and resistant multiple myeloma].

    Terapevticheskii arkhiv·2010
    Same author

    [Pharmacodynamic characteristics of velcade efficacy in resistant and recurrent multiple myeloma: determination of free light chains of blood serum immunoglobulins].

    Terapevticheskii arkhiv·2009
    Same author

    [Clinical characteristics of velcade cumulative effect in resistant and recurrent multiple myeloma].

    Terapevticheskii arkhiv·2008

    Area of Science:

    • Immunology
    • Hematology
    • Oncology

    Background:

    • Multiple myeloma is a plasma cell malignancy characterized by the overproduction of a monoclonal immunoglobulin.
    • Immunoglobulin D (IgD) myeloma is a rare subtype, further classified by the light chain type (kappa or lambda).

    Observation:

    • A case study of a patient with IgD/kappa myeloma is presented, detailing clinical, immunological, and immunochemical findings.
    • This specific immunochemical disease pattern is exceptionally rare in clinical practice.

    Findings:

    • The clinical course of IgD/kappa myeloma was analyzed based on the presented case and existing literature.
    • Compared to IgD/lambda myeloma, the IgD/kappa subtype appears to follow a more favorable disease trajectory.

    Implications:

    • Understanding the distinct clinical behavior of IgD/kappa myeloma is crucial for patient management and prognosis.
    • Further research into the specific characteristics and treatment strategies for rare myeloma subtypes like IgD/kappa is warranted.

    Related Experiment Videos